Mineralys Therapeutics’ (MLYS) Buy Rating Reaffirmed at HC Wainwright
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $42.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 205.90% from the stock’s previous close. […]
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $42.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 205.90% from the stock’s previous close. […]
-logo-1200x675.png?v=20230920074015&w=240&h=240&zc=2){kind=logo}
